Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Assessment of Adherence to and Persistence on Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis

Datos Bibliográficos

ID9099433
AutoresCarlos G Grijalva (0000-0002-2329-7797, Vanderbilt University, autor de correspondencia), Cecilia P Chung (0000-0001-5908-9423), Patrick G Arbogast (Vanderbilt University, autor de correspondencia), Charles M Stein, Charles Stein, EDWARD F MITCHEL (0000-0002-1151-1397, Vanderbilt University, autor de correspondencia), Marie R Griffin (0000-0001-7114-7614, Vanderbilt University, autor de correspondencia)
Año2007
Volumen45
Número10
PáginasS66-S76
Fecha de publicación2007-10-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaMedical Care (JOURNAL)
Identificadores de la revistaISSN: 0025-7079 • E-ISSN: 1537-1948
EditorialOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0b013e318041384c
PMID17909386
OpenAlexW2056070464
IdiomaEN
Citas recibidas2
Referencias citadas42

OBJECTIVE: Biologic disease-modifying antirheumatic drugs (DMARDs) are efficacious for treating rheumatoid arthritis (RA). However, measurements of relative effectiveness, including treatment adherence and persistence, are lacking. We evaluated adherence and persistence during new episodes of use of traditional and biologic DMARDs. METHODS: Using Tennessee Medicaid databases (1995-2004), we assembled a retrospective cohort of patients diagnosed with RA, and identified new episodes of use for 12 DMARD regimens. We evaluated persistence through survival analyses, and adherence within episodes through the medication possession ratio. A risk score was included in the analyses to account for measured confounders. RESULTS: We identified 14,932 patients with RA; 6018 patients had 10,547 episodes of new use of DMARDs. Considering methotrexate as the reference and after adjustment for measured confounders, episodes of new use of sulfasalazine [adjusted hazard ratio (aHR) = 1.59; 95% confidence interval (CI) = 1.47-1.72] and infliximab alone (aHR = 1.37, 95% CI = 1.09-1.73) were more likely to be discontinued; and new episodes of etanercept (aHR = 0.82, 95% CI = 0.73-0.92) and methotrexate + adalimumab (aHR = 0.63, 95% CI = 0.48-0.84) were less likely to be discontinued. Compared with methotrexate, adherence was higher for leflunomide, infliximab, etanercept, and adalimumab and lower for sulfasalazine and all combined therapies. CONCLUSIONS: We developed an approach to assess persistence on and adherence to the most common DMARD therapies. In this large cohort, persistence and adherence to leflunomide and most biologic DMARD therapies were at least comparable to methotrexate. Adherence was lower for sulfasalazine and all combined therapies

Antirheumatic Agents · Antirheumatic drugs · Disease · Intensive care medicine · Persistence (discontinuity) · Physical therapy · Rheumatoid arthritis · Biosimilars and Bioanalytical Methods · Internal Medicine · Medication Adherence and Compliance · Medicine · Rheumatoid Arthritis Research and Therapies

  • Emerging Methods in Comparative Effectiveness and Safety

    Kathleen N Lohr•Medical Care•2007

  • Não adesão à terapia biológica em pacientes com doenças reumáticas no Sistema Único de Saúde em Minas Gerais, Brasil

    Open Access•Clarice Gomes e Souza Dabés, Alessandra Maciel Almeida et al.•Cadernos de Saude Publica•2015

  • The assessment of refill compliance using pharmacy records

    Open Access•J F Steiner, Allan V Prochazka•Journal of Clinical Epidemiology•1997

  • The Robust Inference for the Cox Proportional Hazards Model

    D Y Lin, L J Wei•Journal of the American…•1989

  • Adherence to Medication

    Lars Osterberg, Terrence F Blaschke et al.•New England Journal of Medicine•2005

  • Trends in Prescription Drug Expenditures by Medicaid Enrollees

    Jessica S Banthin, G Edward Miller•Medical Care•2006

Obras citantes distintas2
Citas por año0,11
Intervalo de citas2007 - 2015 (9)
Velocidad de citaciónhistorical
Altamente citadoNo
Tipos de citaNeutras: 2
Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae